S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)
S&P 500   5,092.84 (+0.08%)
DOW   39,245.83 (+0.29%)
QQQ   437.45 (+0.15%)
AAPL   181.98 (-0.30%)
MSFT   410.94 (+0.15%)
META   482.08 (-0.40%)
GOOGL   140.78 (-2.21%)
AMZN   175.25 (+0.15%)
TSLA   194.91 (+1.53%)
NVDA   802.47 (+1.81%)
NIO   5.66 (+4.81%)
AMD   178.11 (+0.90%)
BABA   76.20 (+0.32%)
T   16.79 (-0.06%)
F   12.14 (+0.00%)
MU   90.28 (+4.98%)
CGC   3.42 (+1.79%)
GE   154.13 (+0.52%)
DIS   107.90 (+0.15%)
AMC   4.48 (+0.90%)
PFE   27.46 (-1.08%)
PYPL   59.06 (-0.17%)
XOM   103.57 (-0.26%)

CymaBay Therapeutics (CBAY) News Today

$32.25
+0.02 (+0.06%)
(As of 09:34 AM ET)
SourceHeadline
marketbeat.com logoMonashee Investment Management LLC Acquires New Shares in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
marketbeat.com - February 25 at 10:54 AM
MarketBeat logoCymaBay Therapeutics (NASDAQ:CBAY) Reaches New 12-Month High at $32.25
americanbankingnews.com - February 25 at 2:00 AM
msn.com logoCymaBay Therapeutics (CBAY) Price Target Increased by 12.84% to 31.37
msn.com - February 24 at 8:31 AM
marketbeat.com logoCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Purchased by Swiss National Bank
marketbeat.com - February 23 at 4:26 AM
marketbeat.com logoCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Stake Lessened by Deutsche Bank AG
marketbeat.com - February 22 at 5:25 AM
MarketBeat logoCymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.com
americanbankingnews.com - February 22 at 2:20 AM
finance.yahoo.com logoThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
finance.yahoo.com - February 21 at 9:38 PM
prnewswire.com logoThe New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
prnewswire.com - February 21 at 5:43 PM
MarketBeat logoCymaBay Therapeutics' (CBAY) "Market Perform" Rating Reaffirmed at SVB Leerink
americanbankingnews.com - February 21 at 3:44 AM
MarketBeat logoCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Average Rating of "Hold" by Brokerages
americanbankingnews.com - February 21 at 1:40 AM
msn.com logoLeerink Partners Downgrades CymaBay Therapeutics (CBAY)
msn.com - February 20 at 5:38 PM
globenewswire.com logoCymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - February 20 at 4:05 PM
marketbeat.com logoClariVest Asset Management LLC Sells 63,600 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
marketbeat.com - February 20 at 10:16 AM
marketbeat.com logoSVB Leerink Reaffirms Market Perform Rating for CymaBay Therapeutics (NASDAQ:CBAY)
marketbeat.com - February 20 at 8:18 AM
marketbeat.com logoCymaBay Therapeutics, Inc. (NASDAQ:CBAY) Shares Acquired by New York State Common Retirement Fund
marketbeat.com - February 18 at 4:30 AM
MarketBeat logoCymaBay Therapeutics (NASDAQ:CBAY) Given "Hold" Rating at Jonestrading
americanbankingnews.com - February 17 at 5:04 AM
businesswire.com logoCYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
businesswire.com - February 16 at 1:58 PM
MarketBeat logoCymaBay Therapeutics, Inc. Forecasted to Post FY2026 Earnings of ($0.74) Per Share (NASDAQ:CBAY)
americanbankingnews.com - February 16 at 4:28 AM
MarketBeat logoCymaBay Therapeutics, Inc. to Post FY2026 Earnings of ($0.85) Per Share, William Blair Forecasts (NASDAQ:CBAY)
americanbankingnews.com - February 16 at 4:28 AM
MarketBeat logoCymaBay Therapeutics, Inc. Expected to Earn FY2028 Earnings of $2.18 Per Share (NASDAQ:CBAY)
americanbankingnews.com - February 16 at 4:28 AM
MarketBeat logoCymaBay Therapeutics (NASDAQ:CBAY) Earns "Hold" Rating from Jonestrading
americanbankingnews.com - February 16 at 3:44 AM
MarketBeat logoUBS Group Reiterates Neutral Rating for CymaBay Therapeutics (NASDAQ:CBAY)
americanbankingnews.com - February 16 at 3:44 AM
MarketBeat logoCymaBay Therapeutics (NASDAQ:CBAY) Earns Neutral Rating from BTIG Research
americanbankingnews.com - February 16 at 3:44 AM
MarketBeat logoFY2024 EPS Estimates for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Lifted by Analyst
americanbankingnews.com - February 16 at 2:26 AM
marketbeat.com logoFY2026 Earnings Forecast for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Issued By HC Wainwright
marketbeat.com - February 15 at 8:59 AM
finance.yahoo.com logoCBAY Jan 2026 37.000 call
finance.yahoo.com - February 15 at 8:02 AM
finance.yahoo.com logoCBAY Feb 2024 33.000 call
finance.yahoo.com - February 14 at 8:47 PM
finance.yahoo.com logoCBAY Jan 2025 8.000 put
finance.yahoo.com - February 14 at 8:47 PM
marketbeat.com logoAnalysts Offer Predictions for CymaBay Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:CBAY)
marketbeat.com - February 14 at 9:10 AM
marketbeat.com logoAnalysts see over 50% gains in these 2 mid-cap biotech stocks (CBAY)
marketbeat.com - February 14 at 9:10 AM
marketbeat.com logoCymaBay Therapeutics (NASDAQ:CBAY) Earns Market Perform Rating from Lifesci Capital
marketbeat.com - February 14 at 8:50 AM
marketbeat.com logoCymaBay Therapeutics (NASDAQ:CBAY) Sees Strong Trading Volume
marketbeat.com - February 13 at 12:36 PM
seekingalpha.com logoCymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver Franchise
seekingalpha.com - February 13 at 9:04 AM
marketbeat.com logoBTIG Research Reiterates Neutral Rating for CymaBay Therapeutics (NASDAQ:CBAY)
marketbeat.com - February 13 at 8:41 AM
marketbeat.com logoCampbell & CO Investment Adviser LLC Has $538,000 Stock Position in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)
marketbeat.com - February 13 at 6:30 AM
msn.com logoGilead Eyes Expanded Liver Treatment Portfolio With $4.3 Billion Buyout of CymaBay Therapeutics
msn.com - February 12 at 4:11 PM
msn.com logoLiver disease drug developers rise after Gilead-CymaBay M&A deal
msn.com - February 12 at 4:11 PM
msn.com logoWhy Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion
msn.com - February 12 at 4:11 PM
marketbeat.com logoCymaBay Therapeutics (NASDAQ:CBAY) Stock Rating Reaffirmed by William Blair
marketbeat.com - February 12 at 12:32 PM
marketbeat.com logoCymaBay Therapeutics (NASDAQ:CBAY) Shares Gap Up to $25.69
marketbeat.com - February 12 at 11:23 AM
au.investing.com logoGilead Sciences to acquire CymaBay Therapeutics in $4.3bn cash deal
au.investing.com - February 12 at 10:52 AM
markets.businessinsider.com logoGilead To Acquire CymaBay; To Enhance Revenue Growth Upon Approval Of Seladelpar
markets.businessinsider.com - February 12 at 10:52 AM
msn.com logoGilead to acquire CymaBay for $32.50/share in cash
msn.com - February 12 at 10:52 AM
reuters.com logoDrugmaker Gilead to acquire CymaBay for $4.3 bln
reuters.com - February 12 at 10:52 AM
markets.businessinsider.com logoCymaBay Announces FDA Acceptance Of NDA, Priority Review For Seladelpar; Stock Up 24%
markets.businessinsider.com - February 12 at 10:52 AM
tmcnet.com logoCBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
tmcnet.com - February 12 at 10:52 AM
finance.yahoo.com logoGilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
finance.yahoo.com - February 12 at 10:52 AM
finance.yahoo.com logoUPDATE 2-Drugmaker Gilead to acquire CymaBay for $4.3 bln
finance.yahoo.com - February 12 at 10:52 AM
ca.finance.yahoo.com logoGilead to buy CymaBay for $4.3 billion in bets on liver disease treatment
ca.finance.yahoo.com - February 12 at 10:52 AM
finance.yahoo.com logoCymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
finance.yahoo.com - February 12 at 10:52 AM
Get CymaBay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.



CBAY Media Mentions By Week

CBAY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CBAY
News Sentiment

0.79

0.44

Average
Medical
News Sentiment

CBAY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CBAY Articles
This Week

15

4

CBAY Articles
Average Week

Get CymaBay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CBAY) was last updated on 2/26/2024 by MarketBeat.com Staff